SCHEMBL16765964

SCHEMBL16765964

C[C@H]1C[C@@H](C(=O)Nc2cc(Br)sc2C(N)=O)N(C(=O)OC(C)(C)C)C1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.49
POLB P06746 1/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2C19 P33261 1/20 0.49
LMNA P02545 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
ABL1 P00519 5/20 0.38
BCR P11274 5/20 0.38
HTRA1 Q92743 1/20 0.37
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
USP30 Q70CQ3 2/20 0.36
L3MBTL1 Q9Y468 1/20 0.35
JAK2 O60674 1/20 0.34
NPC1 O15118 1/20 0.34
HDAC8 Q9BY41 3/20 0.34
APOBEC3A P31941 1/20 0.34
APOBEC3G Q9HC16 1/20 0.34
CFD P00746 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14343469 0.86 IKBKB (0.33) CYP1A2POLBCYP3A4CYP2C19LMNA
SCHEMBL16766165 0.85 CYP1A2 (0.43) CYP1A2POLBCYP3A4CYP2C19LMNA
SCHEMBL16766803 0.84 MCL1 (0.45) CYP1A2POLBCYP3A4CYP2C19HTRA1
SCHEMBL16767035 0.83 LMNA (0.58) POLBLMNANPSR1MEN1KMT2A
SCHEMBL16766544 0.82 LMNA (0.55) CYP1A2POLBCYP3A4CYP2C19LMNA
SCHEMBL14343475 0.82 LMNA (0.55) CYP1A2POLBCYP3A4CYP2C19LMNA
SCHEMBL30700627 0.82 CYP1A2 (0.38) CYP1A2POLBCYP3A4CYP2C19LMNA
SCHEMBL16766167 0.82 CYP1A2 (0.38) CYP1A2POLBCYP3A4CYP2C19LMNA
SCHEMBL14343311 0.82 LMNA (0.54) POLBLMNANPSR1MEN1KMT2A
SCHEMBL16766317 0.78 LMNA (0.38) CYP1A2POLBCYP3A4CYP2C19LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3533797-B1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2023-12-20 EP disclosed
US-9388195-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-07-12 US disclosed
US-20150158882-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL (JP) 2015-06-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150158882-A1 HETEROCYCLIC COMPOUND TP53, VHL, MGMT CYP1A2 115/4885POLB 2206/4885CYP3A4 224/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.